Pau Montesinos (P Montesinos)

ORCID

Publication Activity (10 Years)

Years Active: 2015-2024
Publications (10 Years): 81

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Jorge Labrador-Gomez, David Martínez-Cuadrón, Blanca Boluda, Josefina Serrano, Cristina Gil, José A Pérez-Simón, Teresa Bernal, Juan M Bergua, Joaquín Martínez-López, Carlos Rodríguez-Medina, María B Vidriales, Raimundo García-Boyero, Lorenzo Algarra, Marta Polo, María J Sayas, Mar Tormo, Juan M Alonso-Domínguez, Pilar Herrera, Esperanza Lavilla, Fernando Ramos, María L Amigo, Susana Vives, Gabriela Rodríguez-Macías, Armando Mena-Durán, Manuel M Pérez-Encinas, Olga Arce-Fernández, Rebeca Cuello, Joaquín Sánchez-García, María T Gómez-Casares, María C Chillón, María J Calasanz, Rosa Ayala, Rebeca Rodriguez-Veiga, Eva Barragán, Pau Montesinos, null null
Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry. Cancer (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia. Blood advances (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Esperanza Martin-Sanchez, Laura Blanco-Fernández, Peter S Kim, Kamlesh Bisht, Hongfang Wang, Helgi Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesús San F Miguel, Ana Alfonso, Juan-Miguel Bergua, Rebeca Rodriguez-Veiga, Susana Vives, David Martínez-Cuadrón, Pau Montesinos, Juan José Lahuerta, Aintzane Zabaleta
Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia. Blood advances 8 (15) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials. Blood advances 8 (10) (2024)
Antonio Solana-Altabella, Rebeca Rodriguez-Veiga, David Martínez-Cuadrón, Pau Montesinos
A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold? Annals of hematology (2024)
Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan, Yue Zhu, Thomas Prebet, Carlos Enrique Vigil, Iryna Bluemmert, Xin Yu, Courtney D D DiNardo
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials. Blood advances (2024)
Anna Torrent Catarineu, Mireia Morgades, Olga García-Calduch, María Paz Queipo de Llano, Pau Montesinos, Irene Navarro, Jesús María Hernández-Rivas, Abelardo Bárez-García, José González-Campos, Itziar Oiartzabal, Marta Valero, Marta Cervera, Teresa Zudaire Ripa, Manuel Albors-Ferreiro, Oriana Lopez-Godino, Cristina Gil-Cortés, Lucía Villalón, Raquel Saldaña, Josep-María Ribera
Results of the compassionate program of inotuzumab ozogamicin for adult patients with relapsed or refractory acute lymphoblastic leukemia in Spain. European journal of haematology (2023)
Stéphane de Botton, Pierre Fenaux, Karen W L Yee, Christian Recher, Andrew H Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn S Grove, Brian A Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K Hiwase, Joseph G Jurcic, Jürgen Krauter, Xavier G Thomas, Justin M Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge E Cortes
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology 16 (2) (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology (2023)
Farhad Ravandi, Hartmut Döhner, Andrew H Wei, Pau Montesinos, Michael Pfeilstöcker, Cristina Papayannidis, Yinzhi Lai, Kefeng Wang, Wendy L See, Daniel Lopes de Menezes, Erica Petrlik, Thomas Prebet, Gail J Roboz
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001. British journal of haematology (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology (2023)
Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape. Expert review of clinical pharmacology 16 (2) (2023)
Catia Simoes, Sara Villar, Beñat Ariceta, Juan-José Garcés, Leire Burgos, Diego Alignani, Sarai Sarvide, David Martínez-Cuadrón, Juan-Miguel Bergua, Susana Vives, Lorenzo Algarra, Mar Tormo, Pilar Martinez, Josefina Serrano, Pilar Herrera, Fernando Ramos, Olga Salamero, Esperanza Lavilla, Cristina Gil, Jose-Luis Lopez-Lorenzo, Maria-Belen Vidriales, Carmen Chillon, Jorge Labrador, Jose-Francisco Falantes, María-José Sayas, Rosa María Ayala, Joaquin Martinez Lopez, Ana Alfonso Pierola, María-José Calasanz, Felipe Prosper, Jesús San F Miguel, Miguel Á Sanz, Juan José Lahuerta, Pau Montesinos, null null
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia. British journal of haematology (2023)
Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. Cancer chemotherapy and pharmacology (2023)
Mikkael A Sekeres, Pau Montesinos, Jan Novak, Jian-Xiang Wang, Deepa Jeyakumar, Benjamin K Tomlinson, Jiri Mayer, Erin Jou, Tadeusz Robak, David C Taussig, Hervé Dombret, Akil A Merchant, Naveed Shaik, Thomas O'Brien, Whijae Roh, Xueli Liu, Wendy Ma, Christine G DiRienzo, Geoffrey Chan, Jorge E Cortes
Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial. Leukemia (2023)
Joaquin Sanchez-Garcia, Josefina Serrano, Esther Prados de La Torre, Juana Serrano-López, Clara Aparicio-Perez, E Barragán, Pau Montesinos
Identifying prognostic gene panels in acute myeloid leukemia. Expert review of hematology (2023)
Pau Montesinos, Vamsi Kota, Joseph Brandwein, Pierre Bousset, Rebecca J Benner, Erik Vandendries, Ying Chen, Mary Frances McMullin
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia. Cancer chemotherapy and pharmacology (2023)
Sierra Jorge, Pau Montesinos, Xavier Thomas, Laimonas Griskevicius, Thomas Cluzeau, Denis Caillot, Ollivier Legrand, Clara Minotti, Mario Luppi, Firas Farkas, Bourras-Rezki Bengoudifa, Geralyn Gilotti, Sejla Hodzic, Alessandro Rambaldi, Adriano Venditti
Midostaurin plus daunorubicin or idarubicin for young and elderly adults with FLT3-mutated AML: a Phase 3b trial. Blood advances (2023)
Keith W Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A Jonas, Pau Montesinos, Vladimir Ivanov, Andre C Schuh, Courtney D D DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H Wei, Cat N Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia. Blood cancer journal 12 (4) (2022)
Brian A Jonas, Andrew H Wei, Christian Recher, Courtney D D DiNardo, Jun-Ho Jang, Keith W Pratz, Panayiotis Panayiotidis, Pau Montesinos, Su-Peng Yeh, Vladimir Ivanov, Walter Fiedler, Takahiro Yamauchi, Yinghui Duan, Wellington Mendes, Jalaja Potluri, Björn Tews, Yishai Ofran
Timing of response with venetoclax combination treatment in patients with newly diagnosed acute myeloid leukemia. American journal of hematology 97 (8) (2022)
Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang, Ehab Atallah, Gary J Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Tiu, Mark J Levis
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood 139 (23) (2022)
Antonio Solana-Altabella, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia. Expert opinion on emerging drugs 27 (1) (2022)
Catia Simoes, Maria Carmen Chillon, David Martínez-Cuadrón, María-José Calasanz, María-Belén Vidriales, Iria Vazquez, Montserrat Hernández-Ruano, Beñat Ariceta, Paula Aguirre-Ruiz, Leire Burgos, Diego Alignani, Sarai Sarvide, Sara Villar, Ana Alfonso, Felipe Prosper, Rosa María Ayala, Joaquin Martínez-López, Juan-Miguel Bergua, Susana Vives, Jose Antonio Perez-Simon, María García-Fortes, Teresa Bernal Del Castillo, Mercedes Colorado, Mayte Olave, Juan I Rodríguez-Gutiérrez, Jorge Labrador, Marcos González-Díaz, Jesús San F Miguel, Miguel A Sanz, Pau Montesinos, Juan José Lahuerta
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia. Blood advances (2022)
Marina Y Konopleva, Christoph Röllig, Jamie Cavenagh, Dries Deeren, Larisa Girshova, Jürgen Krauter, Giovanni Martinelli, Pau Montesinos, Jonas A Schäfer, Oliver Gerhard Ottmann, Mario Petrini, Arnaud Pigneux, Alessandro Rambaldi, Christian Recher, Rebeca Rodriguez-Veiga, David Taussig, Norbert Vey, Sung Soo Yoon, Marion Ott, Susanne Muehlbauer, Benjamin M Beckermann, Olivier Catalani, Magali Genevray, Kirsten Mundt, Candice Jamois, Pierre Fenaux, Andrew H Wei
Idasanutlin plus cytarabine in relapsed or refractory acute myeloid leukemia: results of the MIRROS trial. Blood advances 6 (14) (2022)
Emilie Bérard, Christoph Röllig, Sarah Bertoli, Arnaud Pigneux, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Müller-Tidow, Claudia Dorothea Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Pierre-Yves Dumas, Pau Montesinos, Christian Recher
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood cancer journal 12 (7) (2022)
Josep-María Ribera, Olga García-Calduch, Jordi Ribera, Pau Montesinos, Isabel Cano-Ferri, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-Lopez, Miriam Santero
Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood advances 6 (18) (2022)
Alexander E Perl, Naoko Hosono, Pau Montesinos, Nikolai A Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C Smith, Mark J Levis, Stephen A Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu, Jessica K Altman
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood cancer journal 12 (5) (2022)
Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Recher, Raphaël A Itzykson, Zdenek Racil, Andrew H Wei, Christoph Schliemann
Revisiting Co-existing Chromosomal Abnormalities in NPM1-mutated AML in Light of the Revised ELN 2022 classification. Blood (2022)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Rebecca Champion, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen Ting, JingZhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jian-Xiang Wang, Qi Jiang, Yan Sun, Brenda Chyla, Wellington L Mendes, Courtney D D DiNardo
Long-term follow-up of VIALE-C in patients with untreated AML ineligible for intensive chemotherapy. Blood (2022)
Hartmut Döhner, Andrew H Wei, Gail J Roboz, Pau Montesinos, Felicitas R Thol, Farhad Ravandi, Hervé Dombret, Kimmo Porkka, Irwindeep Sandhu, Barry Skikne, Wendy L See, Manuel Ugidos, Alberto Risueño, Esther T Chan, Anjan Thakurta, C L Beach, Daniel Lopes de Menezes
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine. Blood 140 (15) (2022)
Eunice S Wang, Pau Montesinos, Mark D Minden, Je Hwan Lee, Michael Heuser, Tomoki Naoe, Wen-Chien Chou, Kamel Laribi, Jordi Esteve, Jessica K Altman, Violaine Havelange, Anne-Marie Watson, Carlo B Gambacorti-Passerini, Elżbieta Patkowska, Shufang Liu, Ruishan Wu, Nisha Philipose, Jason E Hill, Stanley C Gill, Elizabeth Shima Rich, Ramon V Tiu
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood 140 (17) (2022)
Tamara Castaño-Bonilla, Eva Barragán, Claudia Sargas, Alejandro Sanz, Lorenzo Algarra, Pilar Herrera-Puente, Raimundo García-Boyero, Manuel Barrios, David Martínez-Cuadrón, Rebeca Rodriguez-Veiga, Blanca Boluda, Cristina Gil, Josefina Serrano-López, Joaquin Martinez Lopez, María José Sayas-Lloris, María Teresa Olave, Rosalía Riaza-Grau, Teresa Bernal-Del Castillo, María José Larráyoz, Raquel Amigo, Antonio Jiménez-Velasco, Joaquín Sánchez, Rosa María Ayala, Carlos Blas López, Daniel Lainez-González, Juana Serrano-López, Miguel Angel Sanz, Juan Manuel Alonso-Domínguez, Pau Montesinos
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group. Disease markers 2022 (2022)
Stéphane de Botton, Pau Montesinos, Andre Schuh, Cristina Papayannidis, Paresh Vyas, Andrew H Wei, Hans Beier Ommen, Sergey Semochkin, Hee-Je Kim, Richard A Larson, Jamie Koprivnikar, Olga Frankfurt, Felicitas R Thol, Jörg Chromik, Jenny L Byrne, Arnaud Pigneux, Xavier Thomas, Olga Salamero, María-Belén Vidriales, Vadim A Doronin, Hartmut Döhner, Amir T Fathi, Eric Laille, Xin Yu, Maroof Hasan, Patricia Martín-Regueira, Courtney D D DiNardo
Enasidenib vs conventional care in mutant-IDH2 relapsed/refractory acute myeloidleukemia: a randomized, phase 3 trial. Blood (2022)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Don A Stevens, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen B Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Brenda Chyla, Yan Sun, Qi Jiang, Wellington Mendes, John Hayslip, Courtney D DiNardo
6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150). Blood cancer journal 11 (10) (2021)
Laura Cicconi, Maria Luisa Moleti, Pau Montesinos, Eduardo Rego, Hong Hu Zhu, Hiroyuki Takahashi, Michael Dworzak, Elihu Estey, Anthony Schwarer, Aleksandra Holowiecka, Ombretta Annibali, Roberto Castelli, Milena Mirabile, Mario Angelini, Vladimir Lj Lazarevic, Jeevan Kumar, Giuseppe Avvisati, Carmelo Gurnari, Franco Locatelli, Maria Teresa Teresa Voso, Miguel Angel Sanz, Francesco Lo-Coco, Oussama Abla
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood cancer journal 11 (10) (2021)
Blanca Boluda, Antonio Solana-Altabella, Isabel Cano, Evelyn Acuña-Cruz, Rebeca Rodríguez-Veiga, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Ines Gómez, Pilar Solves, Ignacio Lorenzo, Jose Luis Piñana, Jaime Sanz, Manuel Guerreiro, Juan Montoro Gómez, Alvaro Díaz-González, Javier Marco, Albert Blanco, Miguel Angel Sanz, Pau Montesinos
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain. Journal of clinical apheresis 36 (4) (2021)
Hagop M Kantarjian, Kebede H Begna, Jessica K Altman, Stuart L Goldberg, Mikkael A Sekeres, Stephen A Strickland, Martha L Arellano, David F Claxton, Maria R Baer, Marc Gautier, Ellin Berman, Karen Seiter, Scott R Solomon, Gary J Schiller, Selina M Luger, Aleksandra Butrym, Gianluca Gaidano, Xavier G Thomas, Pau Montesinos, David A Rizzieri, Donald P Quick, Parameswaran Venugopal, Rakesh Gaur, Lori J Maness, Tapan Mahendra Kadia, Farhad Ravandi, Marc E Buyse, Judy H Chiao
Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer 127 (23) (2021)
David Martínez-Cuadrón, Juan Eduardo Megías-Vericat, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez-Arbolí, Cristina Gil, Eliana Aguiar, Juan-Miguel Bergua, Jose L Lopez-Lorenzo, Teresa Bernal, Ana Espadana, Mercedes Colorado, Carlos Rodríguez-Medina, María López-Pavia, Mar Tormo, Jesus Lorenzo Algarra, Maria Luz Amigo, Maria Jose Sayas, Jorge Labrador, Juan I Rodríguez-Gutiérrez, Celina Benavente Cuesta, Lissette Costilla-Barriga, Raimundo García-Boyero, Esperanza Lavilla-Rubira, Susana Vives, Pilar Herrera, Daniel García Belmonte, María Mar Herráez-Albendea, Graça V Esteves, María Isabel Gómez-Roncero, Ana Cabello, Guiomar Bautista, Amaia Balerdi, José Mário Mariz, Blanca Boluda, Miguel A Sanz, Pau Montesinos
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood advances (2021)
Juan José Lahuerta, Maria Vidriales Vicente, Amparo Sempere, Fabián Tarín, Enrique Colado, Celina Benavente, María-Teresa Cedena, Joaquín Sánchez, Teresa Caballero-Velazquez, Lourdes Cordon, Juan-José Garcés, Catia Simoes, David Martínez-Cuadrón, Teresa Bernal Del Castillo, Carmen Botella, Sofia Grille, Josefina Serrano, Carlos Rodríguez-Medina, Lorenzo Algarra, Juan Manuel Alonso-Domínguez, María-Luz Amigo, Manuel Barrios, Raimundo García-Boyero, Mercedes Colorado, Jaime Pérez-Oteyza, Manuel Mateo Pérez Encinas, Lisette Costilla-Barriga, María-José Sayas, Olga Pérez, Marcos González-Díaz, José A Pérez-Simón, Joaquin Martinez Lopez, Claudia Sossa, Alberto Orfao, Jesús F San Miguel, Miguel Angel Sanz, Pau Montesinos, null null
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia 35 (8) (2021)
Susana Vives, David Martínez-Cuadrón, Juan Bergua Burgues, Lorenzo Algarra, Mar Tormo, María Pilar Martínez-Sánchez, Josefina Serrano, Pilar Herrera, Fernando Ramos, Olga Salamero, Esperanza Lavilla, José L López-Lorenzo, Cristina Gil, Belén Vidriales, Jose F Falantes, Alfons Serrano, Jorge Labrador, María J Sayas, María Á Foncillas, María L Amador Barciela, María Teresa Olave, Mercedes Colorado, Adriana Gascón, María Á Fernández, Adriana Simiele, Manuel M Pérez-Encinas, Rebeca Rodríguez-Veiga, Olga García, Joaquín Martínez-López, Eva Barragán, Bruno Paiva, Miguel Á Sanz, Pau Montesinos, null null
A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia. Cancer 127 (12) (2021)
Antonio Solana-Altabella, Blanca Boluda, Rebeca Rodríguez-Veiga, Isabel Cano, Evelyn Acuña-Cruz, Albert Blanco, Javier Marco-Ayala, Rosalía de la Puerta, Álvaro Díaz-González, José L Piñana, Jaime Sanz, Amparo Sempere, José Cervera, Eva Barragán, Claudia Sargas, Octavio Ballesta-López, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Miguel Á Sanz, Pau Montesinos
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain. European journal of haematology 106 (5) (2021)
Joshua F Zeidner, Tara L Lin, Carlos E Vigil, Gil Fine, M Yair Levy, Aziz Nazha, Aleksandra Holowiecka, Daniel J Lee, Karen Yee, Andrew Dalovisio, Eunice S Wang, Juan M Bergua Burgues, Jeffrey Schriber, Mark R Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B Douglas Smith
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood cancer journal 11 (10) (2021)
María P Martínez Sánchez, Juan Eduardo Megías-Vericat, Rebeca Rodríguez-Veiga, Susana Vives, Juan Miguel Bergua, Anna Torrent, Sara Suárez-Varela, Blanca Boluda, Joaquín Martínez-López, Isabel Cano-Ferri, Evelyn Acuña-Cruz, Laura Torres-Miñana, Beatriz Martín-Herreros, Alfons Serrano, Amparo Sempere, Eva Barragán, Claudia Sargas, Miguel Sanz, David Martínez-Cuadrón, Pau Montesinos, null null
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients. Annals of hematology 100 (6) (2021)
Christian Recher, Christoph Röllig, Emilie Bérard, Sarah Bertoli, Pierre-Yves Dumas, Suzanne Tavitian, Michael Kramer, Hubert Serve, Martin Bornhäuser, Uwe Platzbecker, Carsten Muller-Tidow, Claudia D Baldus, David Martínez-Cuadrón, Josefina Serrano, Pilar Martínez-Sánchez, Eduardo Rodríguez Arbolí, Cristina Gil, Juan Bergua, Teresa Bernal, Adolfo de la Fuente Burguera, Eric Delabesse, Audrey Bidet, Arnaud Pigneux, Pau Montesinos
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia (2021)
Kendra Sweet, Bhavana Bhatnagar, Hartmut Döhner, Will Donnellan, Olga Frankfurt, Michael Heuser, Vamsi Kota, Hongtao Liu, Emmanuel Raffoux, Gail J Roboz, Christoph Röllig, Margaret M Showel, Stephen A Strickland, Susana Vives, Shijie Tang, Thaddeus J Unger, Anita Joshi, Yao Shen, Mariano J Alvarez, Andrea Califano, Marsha Crochiere, Yosef Landesman, Michael Kauffman, Jatin Shah, Sharon Shacham, Michael R Savona, Pau Montesinos
A 2:1 randomized, open-label, phase II study of selinexor vs. physician's choice in older patients with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma 62 (13) (2021)
Amir T Fathi, Eytan M Stein, Courtney D D DiNardo, Mark J Levis, Pau Montesinos, Stéphane de Botton
Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia. American journal of hematology 96 (6) (2021)
Tomás Palanques-Pastor, Juan Eduardo Megías-Vericat, Pilar Martínez, José Luis López Lorenzo, Javier Cornago Navascués, Gabriela Rodriguez Macias, Isabel Cano, Montserrat Arnan Sangerman, María Belén Vidriales Vicente, Jesús Lorenzo Algarra Algarra, María Ángeles Foncillas, Pilar Herrera, Carmen Botella Prieto, Susana Vives, Ángela Figuera Álvarez, Laida Cuevas Palomares, Marta Anna Sobas, Alejandro Contento Gonzalo, Rebeca Cuello García, María Elena Amutio Diez, Dunia De Miguel Llorente, Begoña Navas Elorza, Juan-Miguel Bergua, Teresa Bernal Del Castillo, María Carmen Mateos Rodríguez, Erik de Cabo López, Ana Carolina Franco Villegas, Raimundo García Boyero, Cristian Escolano Escobar, Cristina Seri Merino, Carlos Cervero, Alicia Roldán Pérez, Lourdes Hermosín Ramos, Marta Cervera Calvo, María Telesa Olave, Paola Villafuerte Gutiérrez, Almudena de Laiglesiai, Josefina Serrano, María Josefa Najera Irazu, José Luis Piñana, Miguel Ángel Sanz, Joaquin Martinez Lopez, Pau Montesinos
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leukemia & lymphoma 62 (12) (2021)
Andrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, Kamel Laribi, Vladimir Ivanov, Inho Kim, Jan Novak, Don A Stevens, Walter Fiedler, Maria Pagoni, Julie Bergeron, Stephen B Ting, Jing-Zhou Hou, Achilles Anagnostopoulos, Andrew McDonald, Vidhya Murthy, Takahiro Yamauchi, Jianxiang Wang, Brenda Chyla, Yan Sun, Qi Jiang, Wellington Mendes, John Hayslip, Courtney D DiNardo
Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy. Blood cancer journal 11 (10) (2021)
Blanca Boluda, David Martínez-Cuadrón, Lorenzo Algarra, Isabel Cano, María J Sayas, Evelyn Acuña-Cruz, Albert Blanco, Javier Marco-Ayala, Rosalía DeLapuerta, Álvaro Díaz-González, María Del Mar Tormo Díaz, Rebeca Rodriguez-Veiga, Raimundo García, José Luis Piñana, María López-Pavía, Eva Barragán, María L Amigo, Claudia Sargas, Aurelio López, Antonio Solana-Altabella, Cristina Gil, Juan Eduardo Megías-Vericat, Miguel Angel Sanz, Pau Montesinos
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients. Leukemia & lymphoma 62 (11) (2021)
Rory Michael Shallis, Maximilian Stahl, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukhereje, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël Itzykson, Blanca Boluda, Florence Rabian, María Del Mar Tormo Díaz, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leukemia & lymphoma 61 (5) (2020)
Octavio Ballesta-López, Antonio Solana-Altabella, Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Pau Montesinos
Gilteritinib use in the treatment of relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Future oncology (London, England) 17 (2) (2020)
Sabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, Gabriel Ghiaur, Xavier Thomas, Marta Sobas, Agnes Guerci-Bresler, Ana Garrido, Arnaud Pigneux, Cristina Gil, Emmanuel Raffoux, Mar Tormo, Norbert Vey, Javier de la Serna, Olga Salamero, Eva Lengfelder, Mark J Levis, Pierre Fenaux, Miguel A Sanz, Uwe Platzbecker, Richard F Schlenk, Lionel Adès, Pau Montesinos
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study. Leukemia 34 (9) (2020)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, María José Herrero, Rebeca Rodríguez-Veiga, Antonio Solana-Altabella, Blanca Boluda, Octavio Ballesta-López, Isabel Cano, Evelyn Acuña-Cruz, José Cervera, José Luis Poveda, Miguel Angel Sanz, Salvador F Aliño, Pau Montesinos
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia. Leukemia & lymphoma 62 (3) (2020)
David Martínez-Cuadrón, Josefina Serrano, Cristina Gil, Mar Tormo, Pilar Martínez-Sánchez, José A Pérez-Simón, Raimundo García-Boyero, Carlos Rodríguez-Medina, María López-Pavía, Celina Benavente, Juan-Miguel Bergua, Esperanza Lavilla-Rubira, María-Luz Amigo, Pilar Herrera, Juan Manuel Alonso-Domínguez, Teresa Bernal Del Castillo, Mercedes Colorado, María J Sayas, Lorenzo Algarra, Maria Vidriales Vicente, Gabriela Rodríguez-Macías, Susana Vives, Manuel Mateo Pérez Encinas, Aurelio López, Víctor Noriega, María García-Fortes, Fernando Ramos, Juan I Rodríguez-Gutiérrez, Lisette Costilla-Barriga, Jorge Labrador, Blanca Boluda, Rebeca Rodriguez-Veiga, Joaquin Martinez Lopez, Miguel Angel Sanz, Pau Montesinos
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? Leukemia 35 (6) (2020)
Josep-María Ribera, Mireia Morgades, Pau Montesinos, Mar Tormo, Daniel Martínez-Carballeira, José González-Campos, Cristina Gil, Pere Barba, Raimundo García-Boyero, Rosa Coll, María Pedreño, Jordi Ribera, Santiago Mercadal, Susana Vives, Andrés Novo, Eulàlia Genescà, Jesús-María Hernández-Rivas, Juan Bergua, María-Luz Amigo, Ferran Vall-Llovera, Pilar Martínez-Sánchez, María Calbacho, Irene García-Cadenas, Antoni Garcia-Guiñon, María-José Sánchez-Sánchez, Marta Cervera, Evarist Feliu, Alberto Orfao, null null
A pediatric regimen for adolescents and young adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: Results of the ALLRE08 PETHEMA trial. Cancer medicine 9 (7) (2020)
Maximilian Stahl, Rory Michael Shallis, Wei Wei, Pau Montesinos, Etienne Lengline, Judith Neukirchen, Vijaya R Bhatt, Mikkael A Sekeres, Amir T Fathi, Heiko Konig, Selina M Luger, Irum Khan, Gail J Roboz, Thomas Cluzeau, David Martínez-Cuadron, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukherjee, Andrew M Brunner, Adam Miller, Christine M McMahon, Ellen K Ritchie, Rebeca Rodríguez-Veiga, Raphaël A Itzykson, Blanca Boluda, Florence Rabian, Mar Tormo, Evelyn Acuña-Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A Podoltsev, Jan Philipp Bewersdorf, Steven Gore, Amer M Zeidan
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia 34 (12) (2020)
María Esther Onecha de la Fuente, Yanira Ruiz-Heredia, David Martínez-Cuadrón, Eva Barragán, Pilar Martinez-Sanchez, María Linares, Inmaculada Rapado, Jaime Perez-Oteyza, Elena Magro, Pilar Herrera, José Luis Rojas, Julián Gorrochategui, Jesús Villoria, Blanca Boluda, Claudia Sargas, Joan Ballesteros, Pau Montesinos, Joaquín Martínez-López, Rosa María Ayala
Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity. British journal of haematology 189 (4) (2020)
Olga Salamero, Pau Montesinos, Christophe Willekens, José Antonio Pérez-Simón, Arnaud Pigneux, Christian Récher, Rakesh Popat, Cecilia Carpio, César Molinero, Cristina Mascaró, Joaquim Vila, M Isabel Arévalo, Tamara Maes, Carlos Buesa, Francesc Bosch, Tim C P Somervaille
First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 38 (36) (2020)
Juan Eduardo Megías-Vericat, Antonio Solana-Altabella, Octavio Ballesta-López, David Martínez-Cuadrón, Pau Montesinos
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia. Annals of hematology 99 (9) (2020)
Mariam Ibáñez, Esperanza Such, Esther Onecha, Inés Gómez-Seguí, Alessandro Liquori, Jorge Sellés, Antonio José Cañada-Martínez, Eva Barragán, Rosa Ayala, Marta LLop, María López-Pavía, Inmaculada Rapado, Alex Neef, Alejandra Sanjuan-Pla, Claudia Sargas, Elisa Gonzalez-Romero, Mireia Boluda-Navarro, Rafa Andreu, Leonor Senent, Pau Montesinos, Joaquín Martínez-López, Miguel Angel Sanz, Guillermo F Sanz, José Cervera
Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype. Scientific reports 10 (1) (2020)
Pau Montesinos, Gail J Roboz, Claude-Eric Bulabois, Marion Subklewe, Uwe Platzbecker, Yishai Ofran, Cristina Papayannidis, Agnieszka Wierzbowska, Ho Jin Shin, Vadim Doronin, Stefan Deneberg, Su-Peng Yeh, Mehmet Ali Ozcan, Steven Knapper, Jorge Cortes, Daniel A Pollyea, Gert Ossenkoppele, Sergio A Giralt, Hartmut Döhner, Michael Heuser, Liang Xiu, Indrajeet Singh, Fei Huang, Julie S Larsen, Andrew H Wei
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 (1) (2020)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Antonio Solana-Altabella, Pau Montesinos
Precision medicine in acute myeloid leukemia: where are we now and what does the future hold? Expert review of hematology 13 (10) (2020)
Jorge E Cortes, Anna Candoni, Richard E Clark, Brian Leber, Pau Montesinos, Paresh Vyas, Amer M Zeidan, Michael Heuser
Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia & lymphoma 61 (14) (2020)
Jordi Ribera, Isabel Granada, Mireia Morgades, Susana Vives, Eulàlia Genescà, Celia González, Josep Nomdedeu, Lourdes Escoda, Pau Montesinos, Santiago Mercadal, Rosa Coll, José González-Campos, Eugenia Abella, Pere Barba, Arancha Bermúdez, Cristina Gil, Mar Tormo, María Pedreño, Daniel Martínez-Carballeira, Jesús-María Hernández-Rivas, Alberto Orfao, Joaquin Martinez Lopez, Jordi Esteve, Pilar Bravo, Antoni Garcia-Guiñon, Guillermo Debén, José M Moraleda, José A Queizán, Xavier Ortín, María J Moreno, Evarist Feliu, Francesc Solé, Josep M Ribera, null null
The poor prognosis of low hypodiploidy in adults with B-cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British journal of haematology 186 (2) (2019)
Juan Eduardo Megías-Vericat, Octavio Ballesta-López, Eva Barragán, Pau Montesinos
IDH1-mutated relapsed or refractory AML: current challenges and future prospects. Blood and lymphatic cancer : targets and therapy 9 (2019)
Juan Eduardo Megías-Vericat, David Martínez-Cuadrón, Miguel Ángel Sanz, José Luis Poveda, Pau Montesinos
Daunorubicin and cytarabine for certain types of poor-prognosis acute myeloid leukemia: a systematic literature review. Expert review of clinical pharmacology 12 (3) (2019)
Josep-María Ribera, Olga García, María-José Moreno, Pere Barba, Irene García-Cadenas, Santiago Mercadal, Pau Montesinos, Manuel Barrios, José González-Campos, Daniel Martínez-Carballeira, Cristina Gil, Jordi Ribera, Susana Vives, Andrés Novo, Marta Cervera, Josefina Serrano, Esperanza Lavilla, Eugenia Abella, Mar Tormo, María-Luz Amigo, María-Teresa Artola, Eulalia Genescà, Pilar Bravo, Daniel García-Belmonte, Antoni García-Guiñón, Jesús-María Hernández-Rivas, Evarist Feliu, null null
Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer 125 (16) (2019)
Pau Montesinos, Juan Bergua, Joana Infante, Jordi Esteve, José Eduardo Guimaraes, Jordi Sierra, Miguel Ángel Sanz
Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. Annals of hematology 98 (11) (2019)
Rebeca Rodríguez-Veiga, Pau Montesinos, Estefanía García, Blanca Boluda, Rafael Rojas, Josefina Serrano, David Martínez-Cuadrón, Carmen Martín, Jaime Sanz, Salvador Tabares, José L Piñana, Ignacio Lorenzo, Juan Montoro, Miguel Salavert, Javier Pemán, Isidro Jarque, Pilar Solves, Guillermo F Sanz, Antonio Torres, Miguel A Sanz
Validation of a multivariable prediction model for post-engraftment invasive fungal disease in 465 adult allogeneic hematopoietic stem cell transplant recipients. Mycoses 62 (5) (2019)
Rebeca Rodríguez-Veiga, Pau Montesinos, Blanca Boluda, Ignacio Lorenzo, David Martínez-Cuadrón, Miguel Salavert, Javier Pemán, Pilar Calvillo, Isabel Cano, Evelyn Acuña, Ana Villalba, José Luis Piñana, Jaime Sanz, Pilar Solves, Leonor Senent, Ana Vicente, Amparo Sempere, José Cervera, Eva Barragán, Isidro Jarque, Antonio Torres, Miguel A Sanz, Guillermo F Sanz
Incidence and outcome of invasive fungal disease after front-line intensive chemotherapy in patients with acute myeloid leukemia: impact of antifungal prophylaxis. Annals of hematology 98 (9) (2019)
Olga Salamero, David Martínez-Cuadrón, Marta Anna Sobas, Celina Benavente, Susana Vives, Javier de laSerna, Manuel Mateo Pérez Encinas, Lourdes Escoda, Cristina Gil, Salut Brunet, Fernando Ramos, Aleksandra Holowiecka, Mariluz Amigo, Isabel Krsnik, Félix Manso, Jesús Arias, José González-Campos, Josefina Serrano, Jalanta Oleksiuk, Manuel Barrios, Raimundo García-Boyero, Andrés Novo, Miguel Angel Sanz, Pau Montesinos, null null
Real life outcomes of patients aged ≥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia & lymphoma 60 (11) (2019)
Jorge Labrador, Elisa Luño, Edo Vellenga, Salut Brunet, José González-Campos, María Carmen Chillón, Aleksandra Holowiecka, Juan-Miguel Bergua, Juan Bergua, José D González-Sanmiguel, Cristina Gil, María Del Mar Tormo Díaz, Olga Salamero, Felix Manso, Isolda I Fernández, Javier de laSerna, María-José Moreno, Manuel Pérez-Encinas, Isabel Krsnik, Josep-María Ribera, Jose Cervera, María J Calasanz, Blanca Boluda, Marta Anna Sobas, Bob Löwenberg, Miguel A Sanz, Pau Montesinos
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia & lymphoma 60 (5) (2018)
Jorge E Cortes, Florian H Heidel, Andrzej Hellmann, Walter Fiedler, B Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A Pollyea, Pierre DesJardins, Oliver Ottmann, Weidong Wendy Ma, M Naveed Shaik, A Douglas Laird, Mirjana Zeremski, Ashleigh O'Connell, Geoffrey Chan, Michael Heuser
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia 33 (2) (2018)
Jorge Gayoso, P Balsalobre, M J Pascual, C Castilla-Llorente, L López-Corral, M Kwon, D Serrano, J L Piñana, P Herrera, C Ferrá, C Pascual, I Heras, Pau Montesinos, A Zabalza, L Bento, A Figuera, I Buño, J L Díez-Martín
Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone marrow transplantation 51 (10) (2016)
E Lengfelder, F Lo-Coco, L Ades, Pau Montesinos, D Grimwade, B Kishore, S M Ramadan, M Pagoni, M Breccia, A J G Huerta, A M Nloga, J D González-Sanmiguel, A Schmidt, J-F Lambert, S Lehmann, E Di Bona, B Cassinat, W-K Hofmann, D Görlich, M-C Sauerland, P Fenaux, M Sanz, null null
Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European LeukemiaNet. Leukemia 29 (5) (2015)

Pau Montesinos.css-eqlu8i{font-size:small;padding-left:4px;} (P Montesinos)

Publication Activity (10 Years)

Top Topics

Top Venues

Pau Montesinos (P Montesinos)